Efpia, the European federation of pharmaceutical industries and associations, has criticised a new US-EU trade agreement as potentially harmful to patients and the European pharma industry and called for exemptions for innovative medicines. The Efpia statement was issued on 21 August shortly after the European Commission published details of the framework agreement setting a maximum, all-inclusive tariff of 15% for the majority of EU exports to the US, including pharmaceuticals. The exact pharma rate is still to be determined but it would not exceed the 15% ceiling.
